Financhill
Back

Reata Pharmaceuticals Quote, Financials, Valuation and Earnings

Sell
34

RETA
Reata Pharmaceuticals

Last Price:
24.02
Seasonality Move:
15.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Reata Pharmaceuticals Price Quote

$24.02
-11.68 (-32.72%)
(Updated: August 8, 2022 at 3:00 PM ET)

Reata Pharmaceuticals Key Stats

Sell
34
Reata Pharmaceuticals (RETA) is a Sell

Day range:
$33.57 - $36.92
52-week range:
$20.24 - $131.51
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
113.32
P/B ratio:
10.19%

Volume:
481.6K
Avg. volume:
301.3K
1-year change:
-72.45%
Market cap:
$1.3B
Revenue:
$11.5M
EPS:
$-8.35

How Much Does Reata Pharmaceuticals Make?

Is Reata Pharmaceuticals Growing As A Company?

  • What Is Reata Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.03%
  • What Is Reata Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Reata Pharmaceuticals Stock Price Performance

What Is Reata Pharmaceuticals 52-Week High & Low?

Reata Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Reata Pharmaceuticals?

Is Reata Pharmaceuticals Cash Flow Positive?

  • What Is RETA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$248.9M
  • What Is Reata Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $4.7M
  • What Is Reata Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.4M

Reata Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    RETA return on invested capital is -121.23%
  • What Is Reata Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -40.62%
  • What Is RETA Return On Equity?
    ROE is a measure of profitability and is -121.23%

Reata Pharmaceuticals Earnings Date & Stock Price

Reata Pharmaceuticals Competitors

Reata Pharmaceuticals Dividend Yield

Data Unavailable

Reata Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 32.03%
Revenue: -3.18% -41.14%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 58.50
Upside from Last Price: 63.87%

Major Shareholders

  • How many RETA shares are owned by institutional investors?
    42.2M RETA shares are owned by institutional investors
  • How many RETA shares are owned by insiders?
    413K RETA shares are owned by insiders